AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension
Completed
- Conditions
- Acute Coronary Syndromes
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2334
- Registration Number
- NCT02305680
- Locations
- 🇨🇳
Research Site, Zhenjiang, China
Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
Phase 1
Completed
- Conditions
- Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
- Interventions
- Drug: Placebo, oral solutionDrug: AZD7986, oral solution, 1 to 50 mg/mL
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 89
- Registration Number
- NCT02303574
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
LUMINIST: LUng Cancer Molecular Insights Non Interventional Study
Completed
- Conditions
- NSCLC
- Interventions
- Other: Data Collection
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 770
- Registration Number
- NCT02300831
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Device: Test GroupOther: Control Group
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 161
- Registration Number
- NCT02300090
- Locations
- 🇬🇧
Research Site, Oldham, UK, United Kingdom
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
- Interventions
- Drug: AZD9291 80 mg/40 mg + placeboDrug: Placebo AZD9291 80 mg/ 40 mg
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 674
- Registration Number
- NCT02296125
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239
- Registration Number
- NCT02288273
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5470
- Registration Number
- NCT02288260
- Locations
- 🇷🇺
Research Site, Vladivostok, Russian Federation
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Placebo matching with Sitagliptin
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 461
- Registration Number
- NCT02284893
- Locations
- 🇿🇦
Research Site, Soweto, South Africa
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Phase 3
Completed
- Conditions
- Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
- Interventions
- Drug: Single agent chemotherapy
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 266
- Registration Number
- NCT02282020
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: TralokinumabOther: Placebo
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT02281357
- Locations
- 🇺🇦
Research Site, Vinnytsia, Ukraine